Nurix Therapeutics (NASDAQ:NRIX) Azioni, Quote.MetaTitle.unusual-options

Nurix Therapeutics

Panoramica

Notizie

Utili

Opzioni

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Comments

Nurix Therapeutics Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO